Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "radiopharmaceuticals" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-11 z 11
    Tytuł:
    Preparation of [61Cu]DTPA complex as a possible PET tracer
    Autorzy:
    Jalilian, A.
    Rowshanfarzad, P.
    Sabet, M.
    Kamalidehghan, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/147476.pdf
    Data publikacji:
    2006
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    copper-61
    DTPA
    labeling
    PET
    radiopharmaceuticals
    Opis:
    Copper-61 (T1/2 = 3.33 h) produced via the 64Zn(p,alfa)61Cu nuclear reaction, using a natural zinc target, was separated from the irradiated target material by two ion exchange chromatography steps and was used for the preparation of [61Cu]-diethylenetriaminepentacetate ([61Cu]DTPA) using freshly-prepared DTPA cyclic dianhydride. An electroplated natural zinc layer on a gold-coated copper backing was irradiated with 22 MeV protons (22 12 MeV on the target, 180 miA irradiation, 3.2 h, final activity 220 GBq of 61Cu2+, RCY > 95%, radionuclidic purity > 99%, 60Cu as the only radionuclidic impurity; T1/2 = 23.7 min). Colorimetric methods showed that traces of chemical impurities in the product were below the accepted limits. The solution of [61Cu]DTPA was prepared with a radiochemical yield of more than 80% starting with 61CuOAc ligand at room temperature after 30 min. RTLC showed the radiochemical purity of more than 99%. The specific activity obtained was about 9.1 TBq/mmol. The tracer was shown to be stable in the final product and in the presence of human serum at 37°C up to 3 h.
    Źródło:
    Nukleonika; 2006, 51, 2; 111-117
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Imaging of hypoxia in small animals with 18F fluoromisonidasole
    Autorzy:
    Kilian, K.
    Rogulski, Z.
    Cheda, Ł.
    Drzał, A.
    Gerszewska, M.
    Cudny, M.
    Elas, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/148618.pdf
    Data publikacji:
    2016
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    18F-fluoromisonidazole
    radiopharmaceuticals
    hypoxia imaging
    Opis:
    A method of automated synthesis of [18F]fluoromisonidazole ([18F]FMISO) for application in preclinical studies on small animals was presented. A remote-controlled synthesizer Synthra RNplus was used for nucleophilic substitution of NITTP (1-(2'-nitro-1'-imidazolyl)-2-O-tetrahydropyranyl-3-O-toluenesulfonyl-propanediol) with 18F anion. Labeling of 5 mg of precursor was performed in anhydrous acetonitrile at 100°C for 10 min, and the hydrolysis with HCl was performed at 100°C for 5 min. Final purifi cation was done with high-performance liquid chromatography (HPLC) and the radiochemical purity of radiotracer was higher than 99%. Proposed [18F]FMISO synthesis was used as a reliable tool in studies on hypoxia in Lewis lung carcinoma (LLC) in mouse models.
    Źródło:
    Nukleonika; 2016, 61, 2; 119-223
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparation and biodistribution of [201Tl](III)vancomycin complex in normal rats
    Autorzy:
    Jalilian, A.
    Hosseini, M.
    Karimian, A.
    Saddadi, F.
    Sadeghi, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/146167.pdf
    Data publikacji:
    2006
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    thallium-201
    vancomycin
    labeling
    SPECT
    radiopharmaceuticals
    infection
    Opis:
    Thallium-201 (T1/2 = 3.04 days) in Tl+ form was converted to Tl3+ cation in presence of O3 in 6 M HCl controlled by RTLC/gel electrophoresis methods. The final evaporated activity was reacted with vancomycin (VAN) in water to yield [201Tl](III)VAN. The best results were obtained at room temperature in water after 30 min with a radiochemical yield > 99%, after mixing the reactants followed by SPE purification using Si Sep-Pak. The studies showed that thallic ion is mostly incorporated into vancomycin with a radiochemical purity of more than 98 š 1% by RTLC. A specific activity of about 4.14 x 1010 Bq/mmol was obtained. Radiochemical purity and stability of 201Tl-VAN in the preparation and in presence of human serum was determined up to 5.5 days. Biodistribution study of 201Tl(III)-vancomycin in normal rats was performed up to 52 h.
    Źródło:
    Nukleonika; 2006, 51, 4; 203-208
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Radioisotopes for medical and industrial use during the 50-year history of the Institute of Nuclear Research
    Autorzy:
    Mikołajczak, R.
    Bazaniak, Z.
    Iller, E.
    Powiązania:
    https://bibliotekanauki.pl/articles/147948.pdf
    Data publikacji:
    2005
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    radiopharmaceuticals
    isotope application
    sealed sources
    radiotherapy
    brachytherapy
    Opis:
    The paper summarises the 50-years long history of the development of research programmes related to the practical applications of radionuclides in various fields of the Polish economy. The changing trends of interest of the potential users are reflected in the research and development activities of the Radioisotope Centre POLATOM. In the 1960's and 1970's the main areas of activity were focused on the sealed sources and radiolabelled compounds for the investigation of industrial processes. The introduction to the routine practice of the RIA and the IRMA kits for hormonal in vitro diagnostics in the 70-ties and 80-ties resulted in the general availability of this diagnostic technique in Poland. The number of radioisotopes having the required radiation type, energy and half-life is steadily increasing due to the progress in irradiation facilities and in chemical separation processes. The need for modern radiopharmaceuticals, more specific and providing higher diagnostic and therapeutic potential as an alternative to other medical modalities is reflected in the research programmes carried out and implemented currently at the Radioisotope Centre POLATOM.
    Źródło:
    Nukleonika; 2005, 50,suppl.3; 83-87
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Enriched water-H2 18 O purification to be used in routine 18FDG production
    Autorzy:
    Al Rayyes, A. H.
    Powiązania:
    https://bibliotekanauki.pl/articles/148761.pdf
    Data publikacji:
    2010
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    H2 18 O
    radiopharmaceuticals
    purification
    18FDG
    Opis:
    18O-water obtained from an 2-deoxy-2-[18F]-fluoro-D-glucose (18FDG, Synthera) synthesis unit is used for purification. The purification process consists of ultraviolet (UV) irradiation followed by a distillation in a preevacuated system. After purification, the loss of enriched water was about only 5 per cent. Organic compounds, radioisotopes, trace metals and gases are eliminated efficiently. Results show that there is no significant difference in the production yield of 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]FDG) whether using purified enriched water by the proposed method of purification or using the new enriched water. This method offers the necessary precaution from contamination by tritium during the purification process. The obtained 18FDG or Na-18F using the purified 18O-water is of tritium free.
    Źródło:
    Nukleonika; 2010, 55, 3; 401-405
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Synthesis of 11C-methionine through gas phase iodination using Synthra MeIPlus synthesis module
    Autorzy:
    Kilian, K.
    Pękal, A.
    Juszczyk, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/148779.pdf
    Data publikacji:
    2016
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    11C-methionine
    11C-radiopharmaceuticals
    gas phase iodination
    Opis:
    A method of 11C-methionine synthesis using ‘bubbling’ method is presented. 11C-methionine was synthesized via 11C methylation from L-cysteine thiolactone (2 mg) in a 300 L solution of 2:1:1 (v/v) 1 M NaOH, ethanol, and water at ambient temperature (85°C, 5 min). The radiochemical purity of radiotracer was higher than 99% and enantiomeric purity (L-11C-methionine) was 91.6 ± 0.4%. The fi nal product met the requirements of European Pharmacopoeia monograph. The proposed 11C-methionine synthesis is a reliable tool for routine manufacturing in clinical applications and animal studies.
    Źródło:
    Nukleonika; 2016, 61, 1; 29-33
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Development of 111In-DTPA-human polyclonal antibody complex for long-term inflammation/infection detection
    Autorzy:
    Jalilian, A.
    Rowshanfarzad, P.
    Shafaii, K.
    Kamali-Dehghan, M.
    Moafian, J.
    Akhlaghi, M.
    Babaii, M.
    Rajabifar, S.
    Mirzaii, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/148870.pdf
    Data publikacji:
    2005
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    radiopharmaceuticals
    indium-111
    human polyclonal antibody
    inflammation
    turpentine oil
    Opis:
    Human polyclonal antibody (HIgG) was successively labeled with 111In-indium chloride after residulation with freshly prepared cyclic DTPA-dianhydride. The best results of the conjugation were obtained by the addition of solid DTPA-dianhydride (0.1 0.3 mg) to 100 mi l of the HIgG solution (0.2 0.4 mg/ml) at pH = 6 in phosphate buffer media at 25°C with continuous stirring for 30 min. Radio-thin-layer chromatography showed an overall radiochemical yield of 96 99% at optimized conditions (specific activity = 300 500 MBq/mg, radiochemical purity >98%). The final isotonic 111In-DTPA-HIgG complex was checked by radio-TLC to ensure the formation of only one species followed by filtration through a 0.22 mi filter. Preliminary long-term in vivo studies in turpentine-oil induced inflammation in rat model was performed to determine late complex distribution of the radioimmunoconjugate. The target/skin and target/ blood ratios were 27 and 51 after 24 h, and 23 and 51 after 110 h, showing a high selectivity of the radiopharmaceutical for inflammatory lesions.
    Źródło:
    Nukleonika; 2005, 50, 3; 91-96
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Production of 18F by proton irradiation of C6H6NF and C6H5NF2
    Autorzy:
    Běták, E.
    Mikołajczak, R.
    Staniszewska, J.
    Mikołajewski, S.
    Rurarz, E.
    Wojtkowska, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/147609.pdf
    Data publikacji:
    2011
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    radiopharmaceuticals
    positron emitters
    radiochemistry
    18F
    cyclotron
    production cross section
    Opis:
    Fluorin--18 can be produced directly by the (p,pn) reaction and also indirectly by the (p,2n) reaction on the 19F target. The overall cross section for both routes is 108 plus or minus 20 mb at 22.5 plus or minus 2.5 MeV. In this work, we obtained 18F, using 25 MeV protons on 2\--fluoroaniline and 2,4-difluoroaniline targets. The chemical separation yield was 46 š 7% and 47 plus or minus 12% for 2-fluoroaniline and 2,4-difluoroaniline, respectively. Low-current 1 h irradiations led to 90 mi Ci of 18F produced from 2-fluoroaniline bombarded with a 70 nA beam (in good agreement with the theoretical value, 96 mi Ci) and to 76 mi Ci of 18F in case of 2,4-difluoroaniline and a 33 nA beam (prediction 85 mi Ci). Both values are close to the thick target result reported by Dmitriev and Molin [4] for 22 MeV protons.
    Źródło:
    Nukleonika; 2011, 56, 4; 269-276
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Radiofarmaceutyki w Instytucie Chemii i Techniki Jądrowej
    Radiopharmaceuticals in Institute of Nuclear Chemistry and Technology
    Autorzy:
    Walczak, R.
    Halik, P.
    Gawęda, W.
    Dziawer, Ł.
    Gumiela, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/214008.pdf
    Data publikacji:
    2018
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    radiofarmaceutyki
    SPECT
    PET
    nanotechnologia
    cholinoesteraza
    teranostyka
    radiopharmaceuticals
    nanotechnology
    cholinesterase
    teranostics
    Opis:
    Instytut Chemii i Techniki Jądrowej jest jedną z nielicznych placówek w Polsce, w których prowadzone są badania nad otrzymywaniem nowych radiofarmaceutyków. Prace w tym zakresie prowadzi Pracownia Badań i Syntezy Radiofarmaceutyków pod kierownictwem prof. dr hab. Aleksandra Bilewicza. Tematyka prowadzonych badań jest ukierunkowana na opracowanie nowych metod produkcji radionuklidów oraz sposobów ich dostarczania do miejsc zmian patologicznych w organizmie człowieka. W artykule przedstawiono opisy badań realizowanych przez doktorantów tej Pracowni w ramach prac doktorskich. Wśród tych prac należy wymienić nanonośniki dla emiterów promieniowania alfa, badania nad inhibitorami cholinoesteraz, nowe metody wytwarzania 99mTc i 43Sc czy produkcję radiofarmaceutyków teranostycznych.
    The Institute of Nuclear Chemistry and Technology is one of the few institutions in Poland, where research on the acquisition of new radiopharmaceuticals is being conducted. The work in this area is carried out by the Laboratory of Research and Synthesis of Radiopharmaceuticals under the supervision of prof. dr hab. Aleksander Bilewicz. The research is focused on the development of new methods of radionuclide production and methods of their delivery to pathological changes in the human body. The article presents descriptions of research carried out by doctoral students as part of their theses. These include the nanocarriers for alpha-emitters, the study of cholinesterase inhibitors, new methods for the production of 99mTc and 43Sc, as well as the production of teranostatic radiopharmaceuticals.
    Źródło:
    Postępy Techniki Jądrowej; 2018, 2; 41-47
    0551-6846
    Pojawia się w:
    Postępy Techniki Jądrowej
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Production of [103Pd]Bleomycin complex for targeted therapy
    Autorzy:
    Jalilian, A.
    Yari-Kamrani, Y.
    Sadeghi, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/147472.pdf
    Data publikacji:
    2006
    Wydawca:
    Instytut Chemii i Techniki Jądrowej
    Tematy:
    palladium-103
    palladium(II) complexes
    radiolabeling
    bleomycin complexes
    radiopharmaceuticals
    cyclotron
    targeted therapy
    Opis:
    Due to the anticancer properties of bleomycin (BLM) complexes, production of [103Pd]bleomycin ([103Pd]BLM) was targeted. Palladium-103 (T1/2 = 16.96 d) was produced via the 103Rh(p,n)103Pd nuclear reaction using a natural rhodium target. Proton energy was 18 MeV with 200 mA irradiation for 15 h (final activity 25.9 GBq of 103Pd2+, RCP > 95%, radionuclidic purity > 99%). 103Pd was separated from the irradiated target by anion exchange using a Dowex 1´8 (Cl-)/100-200 mesh resin in the form of Pd(NH3)2Cl2 in order to react with bleomycin to yield [103Pd]BLM. Chemical purity of the final product was in accordance to the accepted limits. [103Pd]BLM was prepared with a radiochemical yield of more than 98% at 80°C in 30 min. The labeling reaction was optimized for time, temperature and ligand concentration. Radiochemical purity of more than 99% was obtained using RTLC with specific activity of about 370 MBq/mmol. The stability of the tracer was checked in the final product and presence of human serum at up to 3 h. The complex was stable in human serum at 37°C up to 2 h of incubation. Biodistribution studies using a SPECT system performed in normal rats in the first 2-3 h.
    Źródło:
    Nukleonika; 2006, 51, 2; 119-123
    0029-5922
    1508-5791
    Pojawia się w:
    Nukleonika
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Zastosowanie związków kompleksowych rutenu, złota, wanadu, chromu, bizmutu, technetu w medycynie. Cz. 2
    Application of coordination compounds of ruthenium, gold, vanadium, chromium, bismuth, technetium in medicine. Part 2
    Autorzy:
    Pawlak, Marta
    Drzeżdżon, Joanna
    Jacewicz, Dagmara
    Powiązania:
    https://bibliotekanauki.pl/articles/1409708.pdf
    Data publikacji:
    2020
    Wydawca:
    Polskie Towarzystwo Chemiczne
    Tematy:
    związki kompleksowe
    radiofarmaceutyki
    obrazowanie medyczne
    właściwości hipoglikemiczne
    complex compounds
    radiopharmaceuticals
    medical imaging
    hypoglycemic properties
    Opis:
    In this review, the most important complex compounds of ruthenium, gold, vanadium, chromium, bismuth, technetium were selected, and then their most important applications were described in medicine. Ruthenium has been identified as a metal with potential medical use, useful in cancer chemotherapy. The possibility of using its chemical behavior by developing complexes activated for cytotoxic activity through a mechanism of reduction in tumor tissue was discovered. Among the new anti-cancer drugs based on complex compounds, gold compounds have gained a lot of interest. This is due to their strong inhibitory effect on the growth of cancer cells and the observation that many compounds inhibit the enzyme thioredoxin reductase. This enzyme is important for the proliferation of cancerous tissues, and its inhibition is associated with the release of anti-mitochondrial effects. Clinical tests have shown that vanadium compounds can be used as anti-diabetic drugs with low toxicity. However, the therapeutic concentration range is very narrow, just a few micromoles of the compound are enough to cause apoptosis, necrosis and inflammation of healthy cells. Chromium improves the glucose system in people with hypoglycemia or hyperglycemia. Vanadium compounds mainly used to create potential drugs are inorganic compounds such as vanadates(V), vanadyl cation(IV), vanadium oxide(V) and a number of compounds containing organic ligands. Among the metal complexes, chromium(III) picolinate has successfully become a nutrient used to prevent high blood sugar levels. One of the most commonly used bismuth(III) compounds is bismuth subsalicylate. It is one of the few bismuth compounds regularly used to treat various gastrointestinal complaints, including duodenal ulcers. 99mTc injected into the body, depending on its chemical form and molecular structure, concentrates in the examined organ and emits a quantum that allows imaging of the organ through flat scintigraphic or emission processes. The role of complex compounds in medical imaging is largely based on the creation of radiopharmaceuticals for early detection of diseases and cancer radiotherapy. Radiopharmaceuticals are radionuclide-containing drugs and are routinely used in nuclear medicine to diagnose or treat a variety of diseases.
    Źródło:
    Wiadomości Chemiczne; 2020, 74, 11-12; 823-851
    0043-5104
    2300-0295
    Pojawia się w:
    Wiadomości Chemiczne
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-11 z 11

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies